These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24342894)

  • 1. Slow carbamazepine clearance in a nonadherent Malay woman with epilepsy and thyrotoxicosis.
    Yeap LL; Lim KS; Ng CC; Hui-Ping Khor A; Lo YL
    Ther Drug Monit; 2014 Feb; 36(1):3-9. PubMed ID: 24342894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism.
    Puri V; Chaudhry N
    Neurol India; 2004 Mar; 52(1):102-3. PubMed ID: 15069252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.
    Ma CL; Jiao Z; Wu XY; Hong Z; Wu ZY; Zhong MK
    Pharmacogenomics; 2015; 16(13):1499-512. PubMed ID: 26314341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
    Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
    Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.
    Makmor-Bakry M; Sills GJ; Hitiris N; Butler E; Wilson EA; Brodie MJ
    Clin Neuropharmacol; 2009; 32(4):205-12. PubMed ID: 19620853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies].
    Rink T; Wieg C; Schroth HJ; Helisch A; Bertram U
    Nuklearmedizin; 1999; 38(5):156-9. PubMed ID: 10488483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
    Seo T; Ishitsu T; Ueda N; Nakada N; Yurube K; Ueda K; Nakagawa K
    Pharmacogenomics; 2006 Jun; 7(4):551-61. PubMed ID: 16753003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
    Park PW; Seo YH; Ahn JY; Kim KA; Park JY
    J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine.
    Dickinson RG; Hooper WD; Pendlebury SC; Moses D; Eadie MJ
    Clin Exp Neurol; 1988; 25():127-33. PubMed ID: 3077098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis.
    Zhao GX; Shen ML; Zhang Z; Wang P; Xie CX; He GH
    Int J Clin Pharm; 2019 Dec; 41(6):1414-1428. PubMed ID: 31650507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
    Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
    J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
    Jankovic SM; Jovanovic D; Milovanovic JR
    Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thyrotoxic neuromyopathies].
    Sidibe EH; Diagne PM; Ly AB; Ndiaye IP; Sow AM
    Rev Neurol (Paris); 1998 May; 154(4):330-3. PubMed ID: 9773061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
    Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
    Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy.
    Seo T; Nakada N; Ueda N; Hagiwara T; Hashimoto N; Nakagawa K; Ishitsu T
    Clin Pharmacol Ther; 2006 May; 79(5):509-10. PubMed ID: 16678552
    [No Abstract]   [Full Text] [Related]  

  • 18. Daily salivary anticonvulsant monitoring in patients with intractable epilepsy.
    Herkes GK; Eadie MJ
    Clin Exp Neurol; 1989; 26():141-9. PubMed ID: 2642124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
    Grover S; Gourie-Devi M; Baghel R; Sharma S; Bala K; Gupta M; Narayanasamy K; Varma B; Gupta M; Kaur K; Talwar P; Kaur H; Giddaluru S; Sharma A; Brahmachari SK; Indian Genome Variation Consortium ; Kukreti R
    Pharmacogenomics; 2010 Jul; 11(7):927-41. PubMed ID: 20602612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
    Ficker DM; Privitera M; Krauss G; Kanner A; Moore JL; Glauser T
    Neurology; 2005 Aug; 65(4):593-5. PubMed ID: 16116122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.